前言： 目的：合成吉非替尼。
每片含有250毫克吉非替尼。
病人是女性也与对吉非替尼有反应显著相关。
Being female was also significantly associated with response to gefitinib.
如果已经怀孕并服用了吉非替尼，请告知您的医生。
If you become pregnant while taking gefitinib, call your doctor.
急性毒性吉非替尼多达500毫克的临床研究一直很低。
The acute toxicity of gefitinib up to 500 mg in clinical studies has been low.
医生，刚才您所阅读的简介其实就是(吉非替尼)易瑞沙。
Doctor, the profile that you just read is actually for (gefitinib) IRESSA.
相对于化疗病人，用吉非替尼的病人将有更好的生活质量以及更长的存活时间。
Patients treated with gefitinib would live much longer, with better quality of life, than those treated with cytotoxic chemotherapy.
背景：此前的无对照研究显示肺癌一线治疗联合吉非替尼治疗非小细胞肺癌是有效的。
Background: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
初次化疗病人中约有76 ％对吉非替尼有反应， 化疗过的病人中54 ％有反应。
About 76% of the chemotherapy-naive group responded compared to 54% of the chemotherapy-treated group.
接着，我们检测配体依赖的基于受体表达，磷酸化，二聚化的细胞对吉非替尼敏感的机制。
Subsequently, we monitored the ligand-dependent HER profiles based on receptor expression, phosphorylation, and dimerization in conjunction with measurements of cellular susceptibility to gefitinib.
目的观察吉非替尼单药治疗对晚期非小细胞肺癌 （NSCLC）老年患者的效果和安全性。
Objective To evaluate the efficacy and safety of gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
例外的是，这些药物也有临床明显的药物副作用——贝伐单抗可致高血压，吉非替尼和厄洛替尼可有皮肤毒性。
Fortuitously, these drugs also have clinically obvious pharmacodynamic end points-hypertension for bevacizumab and skin toxicity for erlotinib and gefitinib.
然而，无论是抗肿瘤治疗开始后的整体生存率，还是吉非替尼治疗后无恶化生存率在上述两组病人中并无明显差异。
However, neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between groups.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
应用推荐